Halozyme Therapeutics Inc. (HALO)
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
HALO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.47B
- P/E (TTM)
- 32.12
- Forward P/E
- 10.33
- EPS (TTM)
- $3.42
- Dividend yield
- None
- 52-week range
- 61.23 – 116.85
- Day range
- 107.41 – 110.63
- Volume / Avg
- 2.49M / 2.17M
- Beta
- —
- Shares outstanding
- 113.50M
- Next earnings
- Nov 2, 2026
52-week range
HALO stock today
Shares of Halozyme Therapeutics (HALO) finished lower on Oct 8 at $109.84, a drop of 0.86% or $0.95 per share, versus the S&P 500's 0.47% decline. At this level, HALO sits near the top of its 52-week range of $61.23 to $116.85: 6.0% below the high, set on Sep 23, 2026 and 79.4% above the low. HALO is up 64.6% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 67.8%.
At 32.1x trailing earnings, Halozyme Therapeutics trades above the peer-group median of 22.6x. Its forward P/E of 10.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Halozyme Therapeutics's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Halozyme Therapeutics
Company profileHalozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Headquarters
- San Diego, CA
- Employees
- 423
- Website
- halozyme.com
Financial highlights
Full financialsIn fiscal 2025, Halozyme Therapeutics generated $1.40 billion in revenue, up 37.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $316.9 million (-28.6% year over year), for a net margin of 22.7% versus a median of 43.7% in the prior 5 years. Gross margin was 83.6% (down from 84.3%) and operating margin 33.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M |
| Growth | +37.55% | +22.44% | +25.62% | +48.91% | +65.67% |
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$99.56-9.36%
- Strong buy 2
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $2.13
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $1.90 vs —
HALO news
All HALO news- HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeNasdaqHALO, JNJ, MRK, ARGX
- Halozyme Wins Dutch Patent Case Against Merck Over Keytruda SCNasdaqHALO, MRK, ET
- HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXNasdaqHALO, JNJ, ARGX, HOWL
- Halozyme, Argenx Expand ENHANZE Collaboration With Two Additional TargetsNasdaqARGX, HALO
- Why Women-Run Companies Deserve a Place in Your PortfolioNasdaqBMY, TGT, ROST, HALO
- Notable ETF Outflow Detected - XBI, TWST, HALO, NTRANasdaqXBI, TWST, HALO, NTRA
- Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateNasdaqAMGN, ILMN, MRNA, HALO
- State Street SPDR S&P Biotech ETF Experiences Big OutflowNasdaqXBI, TWST, HALO, NTRA
Halozyme Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TECHBio-Techne Corp | 72.45 | -0.11% | $11.36B | vs HALO |
| NBIXNeurocrine Biosciences Inc. | 141.25 | -1.55% | $14.36B | vs HALO |
| EXELExelixis Inc. | 59.02 | +0.99% | $14.62B | vs HALO |
| IBRXImmunityBio Inc. | 9.91 | +1.64% | $10.50B | vs HALO |
| RGENRepligen Corporation | 163.84 | -2.02% | $10.40B | vs HALO |
| QGENQiagen N.V. | 44.53 | -0.58% | $9.20B | vs HALO |
| KYMRKymera Therapeutics Inc. | 109.30 | +0.88% | $8.99B | vs HALO |
| IMVTImmunovant Inc. | 30.26 | -5.56% | $6.25B | vs HALO |
Indexes, lists and sector
Halozyme Therapeutics stock FAQ
What is Halozyme Therapeutics's stock price today?
HALO last traded at $109.84 as of Oct 8, 4:00 PM EDT, down 0.86% on the day. Prices are delayed at least 15 minutes.
When is Halozyme Therapeutics's next earnings date?
Halozyme Therapeutics is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $2.13.
What is HALO's P/E ratio?
HALO trades at a trailing P/E ratio of 32.12 and a forward P/E of 10.33, compared with a median of 22.6 for its closest peers.
Who is Halozyme Therapeutics's CEO?
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. is the chief executive officer of Halozyme Therapeutics Inc., which has about 423 employees.
What is the HALO 52-week high?
The 52-week high for HALO is $116.85 and the 52-week low is $61.23. The stock is currently 6.0% below its high.